Analysts Issue Forecasts for CervoMed FY2026 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at Brookline Capital Markets lifted their FY2026 earnings per share estimates for shares of CervoMed in a note issued to investors on Tuesday, November 10th. Brookline Capital Markets analyst F. Ahmed now expects that the company will post earnings of ($2.21) per share for the year, up from their previous estimate of ($2.97). The consensus estimate for CervoMed’s current full-year earnings is ($2.23) per share. Brookline Capital Markets also issued estimates for CervoMed’s Q4 2026 earnings at ($0.47) EPS.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.09.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Wall Street Zen raised shares of CervoMed from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Chardan Capital raised CervoMed to a “strong-buy” rating in a research report on Monday, August 3rd. HC Wainwright reiterated a “buy” rating on shares of CervoMed in a research note on Monday, October 5th. Finally, Roth Capital set a $7.00 target price on shares of CervoMed in a research report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CervoMed presently has an average rating of “Moderate Buy” and an average price target of $21.00.

CervoMed Price Performance

CRVO stock opened at $1.83 on Friday. CervoMed has a one year low of $1.27 and a one year high of $10.00. The firm has a 50-day simple moving average of $2.36 and a two-hundred day simple moving average of $3.31.

Institutional Investors Weigh In On CervoMed

Large investors have recently modified their holdings of the business. NFSG Corp grew its holdings in CervoMed by 283.3% in the 3rd quarter. NFSG Corp now owns 11,500 shares of the company’s stock valued at $34,000 after buying an additional 8,500 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new stake in shares of CervoMed in the 2nd quarter valued at approximately $116,000. BlackRock Inc. purchased a new stake in shares of CervoMed in the 2nd quarter valued at approximately $167,000. Byrne Asset Management LLC lifted its holdings in shares of CervoMed by 248.6% in the 2nd quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock worth $159,000 after acquiring an additional 36,550 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of CervoMed in the 1st quarter worth approximately $252,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s lead investigational product is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of p38 alpha, an enzyme believed to play a role in neuroinflammation and cognitive decline. CervoMed is primarily evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurological disorder associated with cognitive impairment, fluctuations in attention, visual hallucinations and movement symptoms.